Ranitidin 1A Pharma

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

81 API Suppliers, 30 USDMF, 14 CEP/COS, 2 JDMF, 4 EU WC, 45 KDMF, 9 NDC API, 6 Listed Suppliers, $ API Reference Price

INTERMEDIATES

1 Intermediate Suppliers

1 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

184 FDF Dossiers, 121 FDA Orange Book, 35 Europe, 9 Canada, 19 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - EQ 150MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 300MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE;INJECTION - EQ 25MG BASE/ML, TABLET;ORAL - EQ 75MG BASE, TABLET;ORAL - EQ 150MG BASE

RELATED EXCIPIENT COMPANIES

2 EUROAPI, 4 Rochem International Inc, 8 SPI Pharma, 11 DKSH, 1 Pharm-RX Chemical, 3 Boai NKY Pharmaceuticals Ltd, 8 Gangwal Healthcare, 7 Nanjing Well Pharmaceutical, 5 Kirsch Pharma, 4 ACG Worldwide, 13 Actylis, 1 Aeon Procare, 8 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 16 BASF, 1 Bioplus Life Sciences, 1 Clariant, 10 Corel Pharma Chem, 6 DFE Pharma, 1 Esteem Industries, 3 Finar, 9 Gangwal Chemicals, 4 Ideal Cures, 4 Ingredion Pharma Solutions, 19 Kerry, 3 Keval Exports, 3 Kima Chemical, 6 Lonza Capsugel, 10 Microlex e.U, 1 Nanjing Bold Chemical, 2 Nitika Pharmaceutical Specialities, 2 Nomisma Healthcare, 1 Novo Excipients, 2 Pharmatrans-Sanaq, 7 Pluviaendo, 4 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 2 Qualicaps, 32 Roquette, 13 Seppic, 6 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 11 Sigachi Industries, 4 Silverline Chemicals, 2 The Dow Chemical Company, 1 Ulanqab Kema New Material, 1 Valens Pharmachem, 4 Vasa Pharmachem, 1 Vertellus, 1 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

59 Fillers, Diluents & Binders, 45 Coating Systems & Additives, 27 Thickeners and Stabilizers, 26 Disintegrants & Superdisintegrants, 24 Parenteral, 22 Direct Compression, 22 Film Formers & Plasticizers, 22 Granulation, 22 Taste Masking, 21 Controlled & Modified Release, 20 Solubilizers, 19 Topical, 16 Lubricants & Glidants, 14 Co-Processed Excipients, 9 Chewable & Orodispersible Aids, 9 Empty Capsules, 8 Emulsifying Agents, 7 Rheology Modifiers, 7 API Stability Enhancers, 6 Surfactant & Foaming Agents, 5 Coloring Agents, 4 Vegetarian Capsules, 1 Soft Gelatin

DIGITAL CONTENT

120 News #PharmaBuzz

120 News #PharmaBuzz

GLOBAL SALES INFORMATION

7 Regulatory FDF Prices, 3 Annual Reports

MARKET PLACE

20 APIs

20 APIs

PATENTS & EXCLUSIVITIES

4 Health Canada Patents

4 Health Canada Patents

REF. STANDARDS & IMPURITIES

3 EDQM, 2 JP, 1 Others

ANALYTICAL

1 BioAnalytical Methods

1 BioAnalytical Methods

$ Xls

Filters

Xls

USFDA APPLICATION NUMBER - 18703 / DOSAGE - TABLET;ORAL - EQ 150MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

Ingredient Name	Basis of Strength	Strength
Active Ingredient/Active Moiety
RANITIDINE HYDROCHLORIDE(UNII: BK76465IHM) (RANITIDINE - UNII:884KT10YB7)	RANITIDINE	300mg \| 150mg

Inactive Ingredients

Ingredient Name	GlaxoSmithKline LLC
CROSCARMELLOSE SODIUM(M28OL1HH48)
D&C YELLOW NO. 10(35SW5USQ3G)
FD&C YELLOW NO. 6(H77VEI93A8)
FERRIC OXIDE YELLOW(EX438O2MRT)
HYPROMELLOSE, UNSPECIFIED(3NXW29V3WO)
MAGNESIUM STEARATE(70097M6I30)
MICROCRYSTALLINE CELLULOSE(OP1R32D61U)
TITANIUM DIOXIDE(15FIX9V2JP)
TRIACETIN(XHX3C3X673)

Setid 08010bf7 1f61 48b3 E1b5 7cecb72ba863 Applno 18703 Form Tablet Oral Dosage Eq 150mg Base - Drug Product Composition: Ranitidin 1A Pharma